Stock Research for ATHJF

ATHJF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ATHJF Stock Chart & Research Data

The ATHJF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATHJF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ATHJF Due diligence Resources & Stock Charts

The ATHJF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ATHJF Detailed Price Forecast - CNN Money CNN View ATHJF Detailed Summary - Google Finance
Yahoo View ATHJF Detailed Summary - Yahoo! Finance Zacks View ATHJF Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ATHJF Trends & Analysis - Trade-Ideas Barrons View ATHJF Major Holders - Barrons
NASDAQ View ATHJF Call Transcripts - NASDAQ Seeking View ATHJF Breaking News & Analysis - Seeking Alpha
Spotlight View ATHJF Annual Report - CompanySpotlight.com OTC Report View ATHJF OTC Short Report - OTCShortReport.com
TradeKing View ATHJF Fundamentals - TradeKing Charts View ATHJF SEC Filings - Bar Chart
WSJ View Historical Prices for ATHJF - The WSJ Morningstar View Performance/Total Return for ATHJF - Morningstar
MarketWatch View the Analyst Estimates for ATHJF - MarketWatch CNBC View the Earnings History for ATHJF - CNBC
StockMarketWatch View the ATHJF Earnings - StockMarketWatch MacroAxis View ATHJF Buy or Sell Recommendations - MacroAxis
Bullish View the ATHJF Bullish Patterns - American Bulls Short Pains View ATHJF Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ATHJF Stock Mentions - StockTwits PennyStocks View ATHJF Stock Mentions - PennyStockTweets
Twitter View ATHJF Stock Mentions - Twitter Invest Hub View ATHJF Investment Forum News - Investor Hub
Yahoo View ATHJF Stock Mentions - Yahoo! Message Board Seeking Alpha View ATHJF Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ATHJF - SECform4.com Insider Cow View Insider Transactions for ATHJF - Insider Cow
CNBC View ATHJF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ATHJF - OTC Markets
Yahoo View Insider Transactions for ATHJF - Yahoo! Finance NASDAQ View Institutional Holdings for ATHJF - NASDAQ


Stock Charts

FinViz View ATHJF Stock Insight & Charts - FinViz.com StockCharts View ATHJF Investment Charts - StockCharts.com
BarChart View ATHJF Stock Overview & Charts - BarChart Trading View View ATHJF User Generated Charts - Trading View


Latest Financial News for ATHJF

ATL1103 Phase II trial results published in the European Journal of Endocrinology
Posted on Thursday May 24, 2018

MELBOURNE, Australia, May 24, 2018 /PRNewswire/ -- Antisense Therapeutics (the "Company" or "ANP") is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-reviewed medical journal, the European Journal of Endocrinology. An abstract of the article, titled 'A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly,' is currently available online http://dx.doi.org/10.1530/EJE-18-0138 with the full manuscript to be included in a future print edition and anticipated to be made available free on line in due course. The article highlights the successful outcomes of the Phase II clinical trial of ATL1103 in acromegaly patients where the safety, tolerability, pharmacokinetics and efficacy of two subcutaneous dosing regimens of ATL1103 in 26 adult acromegaly patients dosed with ATL1103 for 13 weeks were assessed.


ATL1103 Phase II Trial Results Published in the European Journal of Endocrinology
Posted on Wednesday May 23, 2018

MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication ...


Approval Received for Phase II Trial of ATL1102 in Duchenne Muscular Dystrophy
Posted on Wednesday February 28, 2018

MELBOURNE, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Antisense Therapeutics ("ANP" or the "Company") (ASX: ANP; OTC PINK: ATHJF) is pleased to advise that the Company has received ...


Antisense Therapeutics Limited (ASX:ANP): Should The Recent Earnings Drop Worry You?
Posted on Tuesday February 13, 2018

When Antisense Therapeutics Limited (ASX:ANP) released its most recent earnings update (30 June 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...


Enter a stock symbol to view the stock details.